Aadi Bioscience, Inc.

Equities

AADI

US00032Q1040

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.34 USD -1.27% Intraday chart for Aadi Bioscience, Inc. +8.84% +15.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Aadi Bioscience, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $6.3M MT
Aadi Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Stock Futures Hover At Start of Busy Week DJ
Aadi Bioscience Reports Supportive Data from Tumor Treatment Trial -- Shares Jump After Hours MT
North American Morning Briefing : Stock Futures -2- DJ
Sector Update: Health Care Stocks Retreating Late Afternoon MT
Top Midday Decliners MT
Piper Sandler Cuts Aadi Bioscience's Price Target to $5 From $30, Keeps Overweight Rating MT
Wall Street Set to Open Narrowly Mixed Ahead of PMI, Industrial Production Data MT
Top Premarket Decliners MT
HC Wainwright Downgrades Aadi Bioscience to Neutral From Buy MT
Transcript : Aadi Bioscience, Inc. - Special Call
Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations CI
Aadi Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Aadi Bioscience, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q3 Revenue $6M MT
Aadi Bioscience Insider Sold Shares Worth $185,750, According to a Recent SEC Filing MT
Aadi Bioscience Insider Sold Shares Worth $179,001, According to a Recent SEC Filing MT
Aadi Bioscience Names Dave Lennon as CEO MT
Aadi Bioscience, Inc. Announces Executive Changes CI
Aadi Bioscience, Inc. Announces Chief Executive Officer Changes CI
Transcript : Aadi Bioscience, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 09:30 AM
Aadi Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chart Aadi Bioscience, Inc.
More charts
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. It has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.34 USD
Average target price
11.67 USD
Spread / Average Target
+398.58%
Consensus